As pro-inflammatory and pro-fibrotic signalling pathways are central mechanisms of diabetic nephropathy and diabetes-associated PT hypertrophy, the effects of SGLT2 inhibitor therapy on such pathways are fundamental for understanding their role in PTs. Here, SLC5A2 is linked to diabetic kidney disease.